Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer

Bibliography

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004;22:3302-8
   PubMed Web of Science ®Google Scholar
• Colozza M, Cardoso F, Sotiriou C, et al. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer 2005;6:61-76
   PubMedGoogle Scholar
• Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16
   PubMed Web of Science ®Google Scholar
• Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47-61
   PubMed Web of Science ®Google Scholar
• Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-7
   Google Scholar
• Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Honig S, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002;346:1832-3
   PubMed Web of Science ®Google Scholar
• Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42
   PubMed Web of Science ®Google Scholar
• Segaloff A, Weeth JB, Meyer KK, et al. Hormonal therapy in cancer of the breast. 19. Effect of oral administration of delta-1-testolactoneon clinical course and hormonal excretion. Cancer 1962;15:633-5
   Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Bonneterre J, Buzdar A, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-9
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9
   PubMed Web of Science ®Google Scholar
• Paridaens R, Therasse P, Dirix L, et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) – a randomized phase III trial of the EORTC Breast Group. Proc ASCO [abstract 515] 2004;23
   Google Scholar
• Miller WR, Dixon JM. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy. Cancer Control 2002;9(Suppl 2):9-15
   PubMedGoogle Scholar
• Bolufer P, Ricart E, Lluch A, et al. Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol 1992;10:438-46
   PubMedGoogle Scholar
• Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-16
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10
   PubMed Web of Science ®Google Scholar
• ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2
   PubMed Web of Science ®Google Scholar
• ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
   PubMed Web of Science ®Google Scholar
• Coates A, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92
   PubMed Web of Science ®Google Scholar
• Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al; for the BIG I-98 Collaborative and the International Breast Cancer Study Group Bern, Switzerland. A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer [abstract 13. Presented at the 31st San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 10–14 December 2008]. Breast Cancer Res Treat 2008;69(Suppl 2):66S
   Google Scholar
• Jones SE, Seynaeve C, Hasenburg C, et al. Results of the first planned analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer [abstract 15. Presented at the 31st San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 10–14 December 2008]. Breast Cancer Res Treat 2009;69(Suppl 2):67S
   Google Scholar
• Jakesz R, Gnant M, Greil R, et al. Tamoxifen and anastrozole as a sequential strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the ABCSG trial 8 [abstract 14. Presented at the 31st San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 10–14 December 2008]. Breast Cancer Res Treat 2009;69(Suppl 2):S67
   Google Scholar
• Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon C, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369:359-70
   Google Scholar
• Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:5138-47
   PubMed Web of Science ®Google Scholar
• Boccardo FM, Rubagotti A, Puntoni M, et al. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial (Meeting Abstracts). Proc Am Soc Clin Oncol. J Clin Oncol 2005;23:526
   Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62
   PubMed Web of Science ®Google Scholar
• Fisher B, Jeong JH, Bryant J, et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364:858-68
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea DW, Hanley K, et al. Attom (Adjuvant tamoxifen – to offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6934 women with estrogen receptor-positive (ER + ) or untested breast cancer – preliminary results [abstract 513]. J Clin Oncol 2008;26(15 Suppl)
   Google Scholar
• Peto R, Davies C; on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women – preliminary results [abstract 48]. Breast Cancer Res Treat 2007;106
   Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793-802
   PubMed Web of Science ®Google Scholar
• Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71
   PubMed Web of Science ®Google Scholar
• Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). JNCI 2007;99:1845-53
   PubMed Web of Science ®Google Scholar
• Schmid M, Jakesz R, Samonigg H, et al. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol 2003;21:984-90
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 2008;26(12):1965-71
   PubMed Web of Science ®Google Scholar
• Powles TJ, Hickish T, Kanis JA, et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14:78-84
   PubMed Web of Science ®Google Scholar
• ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633-43
   PubMed Web of Science ®Google Scholar
• Cella D, Fallowfield L, Barker P, et al. Quality of life of postmenopausal women in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006;100:273-84
   PubMed Web of Science ®Google Scholar
• Gorodeski GI. Update on cardiovascular disease in post-menopausal women. Best Pract Res Clin Obstet Gynaecol 2002;16:329-55
   PubMed Web of Science ®Google Scholar
• Ewer MS, Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009;115(9):1813-26
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Glogorov J. Cardiovascular safety profiles of aromatase inhibitors: a comparative review. Drug Saf 2006;29:785-801
   PubMedGoogle Scholar
• Seruga B, Tannock IF. Upfront use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 2009;27:840-2
   PubMedGoogle Scholar
• Winer EP, Hudis C, Burstein HJ, et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29
   PubMed Web of Science ®Google Scholar
• Gnant M, Jakesz R, Mlineritsch B, et al. Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen – bone density subprotocol results of a randomized multicenter trial (ABCSG-12). Breast Cancer Res Treat 2004;88:S8
   Web of Science ®Google Scholar